Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
27 Mai 2021 - 3:01PM
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage
oncology company focused on developing and commercializing small
molecule therapeutics for patients suffering from rare and
aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief
Executive Officer of Ayala, will participate in two upcoming
virtual investor conferences:
- Jefferies Virtual Healthcare
Conference: Fireside Chat – Wednesday, June 2, 2021 at 3:00 pm
ET.
- Raymond James Human Health
Innovation Conference: Corporate Presentation – Monday, June 21,
2021 at 10:00 am ET.
A live webcast of each event may be accessed by visiting the
Events & Presentations section of Ayala’s website at
ir.ayalapharma.com. An archived replay of each webcast will be
available on the website for approximately 90 days following the
presentations.
About Ayala PharmaceuticalsAyala
Pharmaceuticals, Inc. is a clinical-stage oncology company focused
on developing and commercializing small molecule therapeutics for
patients suffering from rare and aggressive cancers, primarily in
genetically defined patient populations. Ayala’s approach is
focused on predicating, identifying and addressing tumorigenic
drivers of cancer through a combination of its bioinformatics
platform and next-generation sequencing to deliver targeted
therapies to underserved patient populations. The company has two
product candidates under development, AL101 and AL102, targeting
the aberrant activation of the Notch pathway with gamma secretase
inhibitors to treat a variety of tumors including Adenoid Cystic
Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute
Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma
(MM) (in collaboration with Novartis). AL101, has received Fast
Track Designation and Orphan Drug Designation from the U.S. FDA and
is currently in a Phase 2 clinical trial for patients with ACC
(ACCURACY) bearing Notch activating mutations and in a Phase 2
clinical trial for patients with TNBC (TENACITY) bearing Notch
activating mutations and other gene rearrangements. AL102 is
currently being advanced to a Phase 2/3 clinical trials for
patients with desmoid tumors (RINGSIDE) and is being evaluated in a
Phase 1 clinical trial in combination with Novartis’ BMCA targeting
agent, WVT078, in Patients with relapsed/refractory Multiple
Myeloma. For more information, visit www.ayalapharma.com.
Contacts:
Investors:Julie SeidelStern Investor Relations,
Inc. +1-212-362-1200Julie.seidel@sternir.com
Ayala
Pharmaceuticals:+1-857-444-0553info@ayalapharma.com
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Ayala Pharmaceuticals Inc (NASDAQ): 0 Nachrichtenartikel
Weitere News-Artikel